TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Effectiveness and Cost-effectiveness of a Monitoring System for Patients With COPD and Asthma With Persistent Obstruction in Primary Care; a Multicentre Randomised Nested Clinical Trial
Brief Summary: The purpose of this study is to determine the clinical effectiveness and cost-effectiveness of a written expert advice for GPs on additional diagnostic, treatment, and referral of patients based on half-yearly monitoring routines for patients with COPD or ashtma with a persistent obstruction in primary care based on a multicentre randomised nested clinical trial


Options:
A: Arm Label: COPD patients; Type: N/A; Interventions: N/A
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention
C: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Telehealth Pulmonary Rehabilitation | Intervention Type: OTHER; Name: Telehealth Pulmonary Rehabilitation; Assigned to Arm(s): Intervention
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Device: half-yearly monitoring routine | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: half-yearly monitoring routine; Assigned to Arm(s): A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Effectiveness and Cost-effectiveness of a Monitoring System for Patients With COPD and Asthma With Persistent Obstruction in Primary Care; a Multicentre Randomised Nested Clinical Trial
Brief Summary: The purpose of this study is to determine the clinical effectiveness and cost-effectiveness of a written expert advice for GPs on additional diagnostic, treatment, and referral of patients based on half-yearly monitoring routines for patients with COPD or ashtma with a persistent obstruction in primary care based on a multicentre randomised nested clinical trial


Options:
A: Arm Label: Intercom; Type: EXPERIMENTAL; Interventions: Other: INTERdisciplinary COMmunity-based COPD management (INTERCOM) | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: INTERdisciplinary COMmunity-based COPD management (INTERCOM); Assigned to Arm(s): Intercom
B: Arm Label: COPD education + Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: COPD education + Usual care | Arm Label: Physical activity self-management; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity self-management | Intervention Type: BEHAVIORAL; Name: Physical activity self-management; Assigned to Arm(s): Physical activity self-management | Intervention Type: OTHER; Name: COPD education + Usual care; Assigned to Arm(s): COPD education + Usual care
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Device: half-yearly monitoring routine | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: half-yearly monitoring routine; Assigned to Arm(s): A
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self monitoring for patients with COPD; Type: EXPERIMENTAL; Interventions: Procedure: self-monitoring for patients with severe COPD | Arm Label: Nurse monitoring for patients with COPD; Type: EXPERIMENTAL; Interventions: Procedure: nurse-monitoring for patients with severe COPD | Intervention Type: PROCEDURE; Name: self-monitoring for patients with severe COPD; Assigned to Arm(s): Self monitoring for patients with COPD | Intervention Type: PROCEDURE; Name: nurse-monitoring for patients with severe COPD; Assigned to Arm(s): Nurse monitoring for patients with COPD

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Brief Summary: Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is examining the effect of various treatments on cardiovascular disease in people with diabetes. This current study will examine the effects of the ACCORD treatments on the progression of DR in people participating in the ACCORD study.


Options:
A: Intervention Type: DRUG; Name: enalapril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2
C: Arm Label: Intensive glycemia control; Type: EXPERIMENTAL; Interventions: Drug: Hypoglycemic Agents | Arm Label: Standard glycemia control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard glycemia control | Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP treatment | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Arm Label: Fibrate; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate, Drug: Simvastatin | Arm Label: Fibrate Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Hypoglycemic Agents; Assigned to Arm(s): Intensive glycemia control | Intervention Type: DRUG; Name: Standard glycemia control; Assigned to Arm(s): Standard glycemia control | Intervention Type: DRUG; Name: Intensive BP treatment; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): Fibrate | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Fibrate, Fibrate Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fibrate Placebo
D: Arm Label: Nurse administered; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse administered | Arm Label: Nurse & BP monitor; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse administered, Device: BP Monitor | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home BP Monitor; Type: EXPERIMENTAL; Interventions: Device: BP Monitor | Intervention Type: BEHAVIORAL; Name: Nurse administered; Assigned to Arm(s): Nurse & BP monitor, Nurse administered | Intervention Type: DEVICE; Name: BP Monitor; Assigned to Arm(s): Home BP Monitor, Nurse & BP monitor

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient-Centered Online Disease Management Using a Personal Health Record System
Brief Summary: Diabetes is a major, growing, and costly chronic disease in the U.S., and implementation of recommended diabetes care remains poor, not merely suboptimal, and varied for a sizable proportion of Americans with diabetes. To further reduce the treatment and adherence gaps in diabetes care, the researchers propose to evaluate a Customized, Continuous Care Management (CCCM) program that actively supports a partnership between the patient and his/her multidisciplinary care management (CM) team using an online disease management (ODM) system, which is integrated with a comprehensive electronic health record (EHR) system that includes a personal health record and secure patient-clinician messaging capabilities. The CCCM program builds upon CM strategies proven effective in past studies and creates an ODM system that is built upon and fully integrated with a leading, commercially available EHR product - providing a blueprint for instituting customized, continuous care management for many different chronic conditions in a range of ambulatory care settings.


Options:
A: Arm Label: Online disease management; Type: EXPERIMENTAL; Interventions: Behavioral: Online disease management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Online disease management; Assigned to Arm(s): Online disease management
B: Arm Label: Shared Decision Making/Brief Negotiated Interviewing; Type: OTHER; Interventions: Behavioral: Shared Decision Making | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shared Decision Making; Assigned to Arm(s): Shared Decision Making/Brief Negotiated Interviewing
C: Arm Label: Geriatric Diabetes Team Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral | Arm Label: Atention Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral; Assigned to Arm(s): Geriatric Diabetes Team Intervention
D: Arm Label: Information on community resources; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Community Health Worker services; Type: EXPERIMENTAL; Interventions: Behavioral: Community Health Worker (CHW) services | Intervention Type: BEHAVIORAL; Name: Community Health Worker (CHW) services; Assigned to Arm(s): Community Health Worker services

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient-Centered Online Disease Management Using a Personal Health Record System
Brief Summary: Diabetes is a major, growing, and costly chronic disease in the U.S., and implementation of recommended diabetes care remains poor, not merely suboptimal, and varied for a sizable proportion of Americans with diabetes. To further reduce the treatment and adherence gaps in diabetes care, the researchers propose to evaluate a Customized, Continuous Care Management (CCCM) program that actively supports a partnership between the patient and his/her multidisciplinary care management (CM) team using an online disease management (ODM) system, which is integrated with a comprehensive electronic health record (EHR) system that includes a personal health record and secure patient-clinician messaging capabilities. The CCCM program builds upon CM strategies proven effective in past studies and creates an ODM system that is built upon and fully integrated with a leading, commercially available EHR product - providing a blueprint for instituting customized, continuous care management for many different chronic conditions in a range of ambulatory care settings.


Options:
A: Arm Label: Received personal health record; Type: EXPERIMENTAL; Interventions: Other: Electronic personal health record | Arm Label: No personal health record; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic personal health record; Assigned to Arm(s): Received personal health record
B: Arm Label: Electronic disease management decision support; Type: OTHER; Interventions: Other: Electronic disease management decision support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic disease management decision support; Assigned to Arm(s): Electronic disease management decision support
C: Arm Label: Integrated self management support; Type: OTHER; Interventions: Other: Integrated self management support | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Integrated self management support; Assigned to Arm(s): Integrated self management support
D: Arm Label: Online disease management; Type: EXPERIMENTAL; Interventions: Behavioral: Online disease management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Online disease management; Assigned to Arm(s): Online disease management

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Transcranial DC Stimulation Coupled With Constraint Induced Movement Therapy on Motor Function in Stroke Patients
Brief Summary: The purpose of this study is to determine whether a painless and noninvasive procedure called transcranial direct current stimulation (tDCS) combined with a method of physical therapy called constraint-induced movement therapy improves motor function in patients with chronic stroke. Research in healthy subjects has shown that when tDCS is combined with motor learning tasks, there is an increase in learning as compared to motor learning tasks only. The tDCS procedure sessions will be compared to sham (fake) procedure sessions, which is also called placebo stimulation. This study is double blind, which means neither the subjects nor researchers analyzing motor function will know if participants are receiving real tDCS stimulation or placebo. Only the person performing the procedure will know which one participants are receiving. Only by comparing the tDCS procedure to a sham (placebo) procedure can we understand if the tDCS actually improves motor function.

We hypothesize that tDCS will enhance the effects of constraint-induced movement therapy on motor recovery in chronic stroke patients.


Options:
A: Arm Label: Rehabilitation training; Type: EXPERIMENTAL; Interventions: Other: Rehabilitation | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Rehabilitation; Assigned to Arm(s): Rehabilitation training
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy | Intervention Type: DEVICE; Name: Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy; Assigned to Arm(s): 2
C: Arm Label: Active tDCS+ Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Active tDCS, Other: Physical Therapy | Arm Label: Sham tDCS+Physical Therapy; Type: SHAM_COMPARATOR; Interventions: Other: Physical Therapy, Device: Sham tDCS | Intervention Type: DEVICE; Name: Active tDCS; Assigned to Arm(s): Active tDCS+ Physical Therapy | Intervention Type: OTHER; Name: Physical Therapy; Assigned to Arm(s): Active tDCS+ Physical Therapy, Sham tDCS+Physical Therapy | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Sham tDCS+Physical Therapy
D: Arm Label: Sham; Type: PLACEBO_COMPARATOR; Interventions: Device: tDCS | Arm Label: tDCS; Type: EXPERIMENTAL; Interventions: Device: tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): Sham, tDCS

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A DANish Randomized, Controlled, Multicenter Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality. The DANISH Study
Brief Summary: The primary objective of this study is to determine the efficacy of ICD therapy compared with control on the endpoint of death from any cause in patients with heart failure of non-ischemic oetiology.


Options:
A: N/A
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Device: ICD | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimal medical treatment | Intervention Type: DEVICE; Name: ICD; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Optimal medical treatment; Assigned to Arm(s): B
C: Arm Label: 1. Optimal Medical therapy plus ICD; Type: ACTIVE_COMPARATOR; Interventions: Device: Optimal Medical Therapy plus ICD | Arm Label: 2. Optimal Medical Therapy plus CRT/ICD; Type: ACTIVE_COMPARATOR; Interventions: Device: Optimal Medical Therapy plus CRT/ICD | Intervention Type: DEVICE; Name: Optimal Medical Therapy plus ICD; Assigned to Arm(s): 1. Optimal Medical therapy plus ICD | Intervention Type: DEVICE; Name: Optimal Medical Therapy plus CRT/ICD; Assigned to Arm(s): 2. Optimal Medical Therapy plus CRT/ICD
D: Arm Label: CRT OFF; Type: PLACEBO_COMPARATOR; Interventions: Device: Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT | Arm Label: CRT ON; Type: ACTIVE_COMPARATOR; Interventions: Device: Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT | Intervention Type: DEVICE; Name: Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT; Assigned to Arm(s): CRT OFF, CRT ON

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue
Brief Summary: Our research contributes to the understanding of some of the basic biology of the salivary glands. The etiology and many of the pathomechanisms of Sjögren's syndrome are unknown. In particular, reasons for the female dominance, late age of onset, fatigue and the prominent involvement of exocrine glands are unknown. We hypothesize, due to the disease characteristics, that the primary target hit by the disease process is the secretory acinar cell and that this cell is particularly damaged in women due to insufficient support, normally provided by dehydroepiandrosterone and its intracrine processing.


Options:
A: Arm Label: real drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dehydroepiandrosterone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dehydroepiandrosterone; Assigned to Arm(s): real drug | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: dehydroepiandrosterone | Intervention Type: DRUG; Name: dehydroepiandrosterone; Assigned to Arm(s): 2
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo patch | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Testosterone (transdermal patches) | Intervention Type: DRUG; Name: Testosterone (transdermal patches); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo patch; Assigned to Arm(s): 1
D: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Study to Assess the Efficacy and Tolerability of MK8141 in Hypertensive Patients
Brief Summary: This study will evaluate the effectiveness and tolerability of MK8141 in lowering blood pressure in patients who have hypertension (high blood pressure).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MK8141 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MK8141 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enalapril | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Intervention Type: DRUG; Name: MK8141; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
C: Arm Label: Aliskiren 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Aliskiren 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Aliskiren 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Ramipril 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren 150 mg, Aliskiren 300 mg, Aliskiren 75 mg | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril 5 mg
D: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Open-Label Phase IV Mono Centre Study to Compare the Response Profiles of Montelukast Versus Fluticasone in Children With Pre-School Asthma
Brief Summary: Explorative comparison of montelukast with inhaled steroids (fluticasone) to estimate responder profiles, in terms of symptom scores, rescue medication, increase of FEV1, in correlation to presence of allergy, bronchial hyperreactivity (PD20), exhaled NO, excretion of leukotrienes, response to RABA and laboratory parameters in patients with pre-school asthma i.e. asthma phenotypes.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A
C: Arm Label: Sequence #1; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #2; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #3; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #4; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #5; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #6; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Intervention Type: DRUG; Name: fluticasone propionate + montelukast; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate + salmeterol; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): 2

Answer: D